Novolog (Pharm-Up 1966) Future Growth

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Novolog (Pharm-Up 1966) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TASE:NVLG - Analysts future estimates and past financials data (ILS Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	1,668	-20	86	153	N/A
12/31/2023	1,643	-42	129	200	N/A
9/30/2023	1,630	15	177	252	N/A
6/30/2023	1,597	25	222	295	N/A
3/31/2023	1,546	25	66	145	N/A
12/31/2022	1,508	48	63	133	N/A
9/30/2022	1,424	43	79	137	N/A
6/30/2022	1,366	43	72	121	N/A
3/31/2022	1,315	41	69	101	N/A
12/31/2021	1,255	42	53	83	N/A
9/30/2021	1,229	41	21	47	N/A
6/30/2021	1,190	40	32	58	N/A
3/31/2021	1,148	40	41	67	N/A
12/31/2020	1,134	40	33	58	N/A
9/30/2020	1,085	38	-7	20	N/A
6/30/2020	1,061	24	-30	-4	N/A
3/31/2020	1,042	18	39	64	N/A
12/31/2019	1,004	10	76	101	N/A
9/30/2019	1,000	9	134	157	N/A
6/30/2019	963	18	144	165	N/A
3/31/2019	943	22	49	76	N/A
12/31/2018	910	23	-5	24	N/A
9/30/2018	912	22	10	48	N/A
6/30/2018	891	23	36	79	N/A
3/31/2018	862	22	7	47	N/A
12/31/2017	839	23	N/A	86	N/A
9/30/2017	797	23	N/A	20	N/A
6/30/2017	780	24	N/A	33	N/A
3/31/2017	770	27	N/A	-8	N/A
12/31/2016	739	29	N/A	20	N/A
9/30/2016	730	28	N/A	151	N/A
12/31/2015	683	25	N/A	140	N/A
12/31/2014	629	24	N/A	161	N/A
12/31/2013	543	15	N/A	-56	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NVLG's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if NVLG's earnings are forecast to grow faster than the IL market

High Growth Earnings: Insufficient data to determine if NVLG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NVLG's revenue is forecast to grow faster than the IL market.

High Growth Revenue: Insufficient data to determine if NVLG's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NVLG's Return on Equity is forecast to be high in 3 years time

Novolog (Pharm-Up 1966) Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

First quarter 2024 earnings released: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023)

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2024 Results on May 21, 2024

Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022)

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: ₪0.001 (vs ₪0.02 in 3Q 2022)

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: ₪0.023 (vs ₪0.024 in 2Q 2022)

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

First quarter 2023 earnings released: ₪0.02 loss per share (vs ₪0.024 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: ₪0.094 (vs ₪0.084 in FY 2021)

Investor sentiment deteriorates as stock falls 17%

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2022 Results on Mar 20, 2023

Investor sentiment deteriorates as stock falls 15%

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Third quarter 2022 earnings released: EPS: ₪0.02 (vs ₪0.02 in 3Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: EPS: ₪0.024 (vs ₪0.02 in 2Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2022 Results on Aug 10, 2022

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2022 Results on May 18, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2021 Results on Mar 14, 2022

Third quarter 2021 earnings released: EPS ₪0.022 (vs ₪0.021 in 3Q 2020)

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Upcoming dividend of ₪0.032 per share

Full year 2020 earnings released: EPS ₪0.086 (vs ₪0.026 in FY 2019)

Novolog (Pharm-Up 1966) Ltd to Report Fiscal Year 2020 Results on Mar 17, 2021

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

New 90-day low: ₪2.76

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Novolog (Pharm-Up 1966) Ltd announced that it has received ILS 119.999999 million in funding

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Third quarter 2020 earnings released: EPS ₪0.021

Market bids up stock over the past week

New 90-day high: ₪3.20

New 90-day high - ₪3.09

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies